Wedbush Reaffirms Outperform Rating for G1 Therapeutics (NASDAQ:GTHX)

Wedbush reissued their outperform rating on shares of G1 Therapeutics (NASDAQ:GTHX) in a research note released on Monday, RTT News reports. They currently have a $3.00 target price on the stock, down from their prior target price of $5.00.

A number of other research firms have also recently commented on GTHX. Needham & Company LLC reissued a buy rating and set a $12.00 target price on shares of G1 Therapeutics in a research report on Thursday, June 13th. HC Wainwright reissued a buy rating and set a $9.00 target price on shares of G1 Therapeutics in a research report on Tuesday, May 28th.

G1 Therapeutics Trading Up 2.3 %

Shares of GTHX stock opened at $2.25 on Monday. The stock has a market cap of $117.63 million, a price-to-earnings ratio of -3.63 and a beta of 1.71. The company has a quick ratio of 2.55, a current ratio of 2.94 and a debt-to-equity ratio of 1.34. G1 Therapeutics has a fifty-two week low of $1.08 and a fifty-two week high of $6.14. The firm’s 50 day moving average price is $3.71 and its two-hundred day moving average price is $3.59.

G1 Therapeutics (NASDAQ:GTHX) last announced its quarterly earnings results on Wednesday, May 1st. The company reported ($0.20) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.01). The business had revenue of $14.48 million for the quarter, compared to analyst estimates of $15.21 million. G1 Therapeutics had a negative net margin of 36.40% and a negative return on equity of 74.75%. During the same period last year, the firm earned ($0.53) earnings per share. On average, analysts anticipate that G1 Therapeutics will post -0.53 EPS for the current year.

Institutional Trading of G1 Therapeutics

Institutional investors have recently added to or reduced their stakes in the stock. Creative Financial Designs Inc. ADV raised its holdings in G1 Therapeutics by 98.1% in the fourth quarter. Creative Financial Designs Inc. ADV now owns 35,280 shares of the company’s stock valued at $108,000 after acquiring an additional 17,475 shares in the last quarter. Jump Financial LLC acquired a new stake in G1 Therapeutics in the fourth quarter valued at $105,000. Connor Clark & Lunn Investment Management Ltd. raised its holdings in G1 Therapeutics by 68.3% in the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 204,200 shares of the company’s stock valued at $294,000 after acquiring an additional 82,879 shares in the last quarter. Acadian Asset Management LLC acquired a new stake in G1 Therapeutics in the third quarter valued at $189,000. Finally, abrdn plc acquired a new stake in G1 Therapeutics in the fourth quarter valued at $1,293,000. 24.21% of the stock is owned by institutional investors and hedge funds.

G1 Therapeutics Company Profile

G1 Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer in the United States. The company offers COSELA, which helps to decrease incidence of chemotherapy-induced myelosuppression in adult patients treated with a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive stage small cell lung cancer.